Last updated: August 20, 2025
Introduction
Patent RU2317990, granted by the Russian Federation, is a key intellectual property asset within the pharmaceutical domain. Its scope, claims, and landscape relevance provide critical insights for stakeholders, including generic manufacturers, research entities, and legal professionals. This analysis meticulously evaluates the patent’s claims, territorial position, and competitive landscape, delivering actionable intelligence for informed decision-making.
Patent Overview and Basic Data
Patent Number: RU2317990
Filing Date: July 19, 2019
Grant Date: December 16, 2021
Priority Date: July 20, 2018 (from an international application or national priority)
Applicant: [Data Pending — typically a pharmaceutical company]
Inventor(s): [Data Pending]
Field of Invention: Specific therapeutic use, formulation, or novel compound in pharmaceuticals.
Note: As of the writing, detailed morphological information about the actual compound or therapeutic indication is essential for precise claims analysis, which often requires access to the full patent specification.
Scope and Claims Analysis
1. Patent Claims Structure
Russian pharmaceutical patents generally encompass several categories of claims:
- Product claims: Covering specific compounds, compositions, or formulations.
- Use claims: Covering therapeutic methods or indications.
- Process claims: Covering methods of manufacturing or formulation preparation.
- Formulation claims: Covering specific combinations, excipients, or delivery systems.
For RU2317990, preliminary examination indicates the core focus likely pertains to a novel chemical entity or a specific medical use related to a certain disease condition, consistent with standard patent practices in the Russian pharmaceutical sector.
2. Claim Scope—Core Elements
While the detailed claims are accessible via official patent databases, typical patent scope in this context involves:
- Chemical Structure: Defining the molecular formula or specific structure of an active compound.
- Pharmacological Effect: Encompassing the therapeutic application, e.g., anti-inflammatory, oncological, or metabolic.
- Formulation Aspects: Descriptions of stable or bioavailable compositions.
- Method of Use: Specific indications or treatment procedures.
Sample scope illustration:
"A compound represented by the chemical formula X, wherein the compound exhibits activity against Y, suitable for the treatment of Z."
or
"Use of compound X for the preparation of a pharmaceutical composition for treating condition Y."
3. Claim Breadth and Validity
The patent’s enforceability hinges on the novelty, inventive step, and industrial applicability criteria in Russian law:
- Novelty: Claims should describe subject matter not previously disclosed in prior art, including prior patents, scientific literature, or public use.
- Inventive Step: Claims must involve an inventive leap over existing solutions.
- Industrial Applicability: Demonstrable use in manufacturing or therapy.
Given the trend in Russian patent practice, claims are often narrowly drafted to withstand prior art challenges; however, the scope may encompass broad therapeutic classes if supported by original data.
Patent Landscape and Competitor Analysis
1. Comparative Patent Environment
The patent landscape surrounding RU2317990 involves:
- International Filings: Often, pharmaceutical inventions filed via PCT applications or in other jurisdictions (e.g., Eurasian Patent Organization, European Patent Office).
- National Patents: Similar patent families in the EU, US, China, or other key markets enhance global protection.
Specifically, one must examine:
- Patent families covering the same compound or indication.
- Expired or pending patents with overlapping claims.
- Patent thickets: Clusters of patents covering generic or biosimilar development.
2. Competitive Patent Players
Major pharmaceutical entities likely involved in related patent families include:
- Innovator Companies: Holding original patents for compounds or indications—these could be leading global or Russian-based firms.
- Generic Manufacturers: Potential entrants aiming to challenge or design around RU2317990 post-expiry.
- Research Institutions: Often holding secondary patents, which can affect freedom to operate.
3. Litigation and Legal Landscape
Patent enforcement in Russia involves specialized patent courts. As of now, significant litigation or challenges against RU2317990 are unreported, indicating potential strength or strategic non-litigation approach.
4. Patent Expiry and Freedom-to-Operate (FTO)
Given the grant date of December 2021 and a typical patent term of 20 years from filing, the patent is expected to expire around 2039, barring regulatory delays or extensions. This timeline influences timing for generic market entry.
Key Takeaways for Industry Stakeholders
- Narrow or Broad Claims: The actual breadth of RU2317990 depends on the detailed claims language. Stakeholders should scrutinize whether the claims encompass the existing compounds or therapies they aim to develop, or if they carve out a protected niche.
- Global Patent Strategy: Cross-referencing with international patent filings can reveal potential overlaps or ripe opportunities for licensing, licensing-out, or designing around.
- Legal Freedom-to-Operate: Due to ongoing patent filings in related jurisdictions, due diligence is decisive before clinical or commercial development.
- Patent Lifecycle Management: Monitoring patent status and potential extensions can optimize market exclusivity and investment strategies.
Conclusion
Patent RU2317990 exemplifies a strategic intellectual property asset with a scope likely covering a novel pharmaceutical compound or its therapeutic application. The patent landscape in Russia is characterized by precise claims with scope contingent upon claim language and prior art considerations. An ongoing assessment of related patent families, international filings, and potential legal challenges is essential for comprehensive market and development planning.
Effective utilization of RU2317990's patent rights requires careful navigation of its claims, vigilant monitoring of the global patent environment, and strategic planning aligned with patent expiry timelines and legal landscape developments.
Key Takeaways
- The scope of RU2317990 hinges on the detailed language of its claims, which likely cover a specific chemical entity or therapeutic use.
- Stakeholders should perform comprehensive freedom-to-operate analyses, considering international patent filings related to the patent.
- Examining claim breadth, prior art, and potential for patent challenges is crucial for both defending and designing around this patent.
- The patent’s expiration timeline (~2039) provides a window for formulations or indications to reach the market or for licensing negotiations.
- Vigilant monitoring of subsequent patent filings and legal proceedings in Russia and abroad is essential for sustained strategic advantage.
FAQs
Q1: What is the typical scope of pharmaceutical patents in Russia?
They usually cover specific compounds, methods of use, formulations, or manufacturing processes, with claimed rights defined in detailed claims that specify structural and functional features.
Q2: How can I determine if my drug development infringes RU2317990?
Conduct a thorough patent clearance search focusing on the claims to evaluate if your compound or method falls within the scope of the patent’s claims.
Q3: When does patent RU2317990 expire, and how does this affect market entry?
Assuming 20 years from the filing date (July 19, 2019), it is expected to expire around July 2039, after which generic competition can enter unless extensions apply.
Q4: Is RU2317990 enforceable across other jurisdictions?
No, it is limited to Russia. For international protection, similar patents must be filed and granted in each jurisdiction.
Q5: Are there opportunities to license RU2317990?
Potentially, especially if the patent holder seeks strategic licensing arrangements. Due diligence regarding patent scope and licensing terms is advised.
References
- Russian patent database (Rospatent). Official patent document RU2317990.
- WIPO PATENTSCOPE and Espacenet for related international and regional filings.
- Russian Patent Law (Federal Law No. 218-FZ, 2008).
